Abstract

A NEW WEAPON AGAINST RESISTANT TUBERCULOSISBEDAQUILINE

Anand vardhan, C. Dinesh M. Naidu, Mangesh Bankar, Sagar Sharma, Vinay Raghuvanshi

Abstract

Multidrug resistant tuberculosis is defined as resistance to at least isoniazid and rifampicin. Multidrug resistant Tuberculosis is becoming a challenging health problem. There is a need need for newer and more effective drugs for this deadly menance. Bedaquiline, first in a new class of drug, is approved by the US Food and Drug Association against MDR Tuberculosis. In phase III trials Bedaquiline is now known to bring about faster culture conversions. Accordingly, the FDA has approved bedaquiline as part of combination therapy to treat adults with MDR pulmonary TB but should be used only when other alternatives are not available. Bedaquiline a promising potential is also having a favourable outcome in Multi-Drug Resistant Tuberculosis.

Keywords: Bedaquiline, multi drug reisitant, tuberculosis.